Published in AIDS Weekly, November 8th, 2004
The agreement grants Calypte access to Ani's new patent pending rapid diagnostic test platform and sample applicator technology. In consideration for the worldwide license, Ani will receive a license fee and future royalties based upon sales in the worldwide professional and OTC human in-vitro diagnostic testing markets.
Under the terms of the agreement, Calypte has been granted an exclusive license to develop, manufacture and sell rapid diagnostic tests for several sexually...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.